Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Morgenstern

Internal Medicine Springfield, OH Medical Doctor

NPI 1417916651 CMS profile 63793

247 S Burnett Rd, Springfield, OH 45505

Open in the dashboard

General payments

$12,602

893 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Morgenstern of Springfield, OH is reported in the CMS Open Payments database as having received $12,602 across 893 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $90 1
2024 General $547 5
2023 General $2,129 135
2022 General $2,565 173
2021 General $2,775 224
2020 General $2,114 155
2019 General $2,382 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Morgenstern
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Steven Morgenstern were reported at $90. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Steven Morgenstern Internal Medicine median Middle half National median
2019 $2,382 $159 $48–$570 $163
2020 $2,114 $119 $33–$402 $114
2021 $2,775 $135 $37–$521 $132
2022 $2,565 $141 $42–$496 $149
2023 $2,129 $149 $45–$519 $160
2024 $547 $154 $47–$537 $164
2025 $90 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,088 82 payments
  2. AbbVie, Inc. $1,884 158 payments
  3. Pfizer Inc. $937 85 payments
  4. Lilly USA, LLC $832 58 payments
  5. Merck Sharp & Dohme Corporation $691 49 payments
  6. Amgen Inc. $644 37 payments
  7. Amarin Pharma Inc. $587 52 payments
  8. Allergan Inc. $510 55 payments
  9. GlaxoSmithKline, LLC. $467 25 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $464 23 payments
  11. Other $3,498 269 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,591 891 payments
  2. Education $11 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $1,585 64 payments
  2. VRAYLAR $857 70 payments
  3. UBRELVY $584 45 payments
  4. BREZTRI $564 15 payments
  5. Vascepa $534 48 payments
  6. Kerendia $464 23 payments
  7. JANUVIA $451 34 payments
  8. STEGLATRO $438 35 payments
  9. AIMOVIG $426 31 payments
  10. JANUMET $409 30 payments
  11. Other $11,069 838 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 191 drugs

Part D claims

11,571

Median for Internal Medicine: 777

Drug cost

$836,917

Median for Internal Medicine: $73,373

Branded share of claims

25.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 103 $83,582
Ozempic Semaglutide Brand 71 $69,510
Eliquis Apixaban Brand 79 $69,151
Farxiga Dapagliflozin Propanediol Brand 72 $68,056
Januvia Sitagliptin Phosphate Brand 57 $49,533
Xarelto Rivaroxaban Brand 42 $43,994
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $43,876
Mounjaro Tirzepatide Brand 33 $37,664
Tradjenta Linagliptin Brand 28 $30,587
Trulicity Dulaglutide Brand 19 $30,581

The 10 drugs with the highest cost, of 191 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$44,893

Of which drugs: $1,874

Medicare patients

222

Average age 74

Services billed

640

114 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 31%
Ischemic heart disease 29%
COPD 24%
Chronic kidney disease 23%
Depression 23%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 17 17 $1,321

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $125
$125 — —
AREXVY
  • GlaxoSmithKline, LLC. $125
$125 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $122
$122 72 —
VRAYLAR
  • AbbVie, Inc. $71
$71 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

893 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record